Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations

P. Rajwa, F. Quhal, B. Pradere, G. Gandaglia, G. Ploussard, MS. Leapman, JL. Gore, A. Paradysz, D. Tilki, AS. Merseburger, TM. Morgan, A. Briganti, GS. Palapattu, SF. Shariat

. 2023 ; 20 (4) : 205-216. [pub] 20230104

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010581
E-zdroje Online Plný text

NLK ProQuest Central od 2009-04-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2009-04-01 do Před 1 rokem

Odkazy

PubMed 36600087
DOI 10.1038/s41585-022-00680-4
Knihovny.cz E-zdroje

Mutations in the BRCA1 and BRCA2 tumour suppressor genes are associated with prostate cancer risk; however, optimal screening protocols for individuals with these mutations have been a subject of debate. Several prospective studies of prostate cancer incidence and screening among BRCA1/2 mutation carriers have indicated at least a twofold to fourfold increase in prostate cancer risk among carriers of BRCA2 mutations compared with the general population. Moreover, BRCA2 mutations are associated with more aggressive, high-grade disease characteristics at diagnosis, more aggressive clinical behaviour and greater prostate cancer-specific mortality. The risk for BRCA1 mutations seems to be attenuated compared with BRCA2. Prostate-specific antigen (PSA) measurement or prostate magnetic resonance imaging (MRI) alone is an imperfect indicator of clinically significant prostate cancer; therefore, BRCA1/2 mutation carriers might benefit from refined risk stratification strategies. However, the long-term impact of prostate cancer screening is unknown, and the optimal management of BRCA1/2 carriers with prostate cancer has not been defined. Whether timely localized therapy can improve overall survival in the screened population is uncertain. Long-term results of prospective studies are awaited to confirm the optimal screening strategies and benefits of prostate cancer screening among BRCA1/2 mutation carriers, and whether these approaches ultimately have a positive impact on survival and quality of life in these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010581
003      
CZ-PrNML
005      
20230801132518.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41585-022-00680-4 $2 doi
035    __
$a (PubMed)36600087
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland $1 https://orcid.org/0000000340736584
245    10
$a Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations / $c P. Rajwa, F. Quhal, B. Pradere, G. Gandaglia, G. Ploussard, MS. Leapman, JL. Gore, A. Paradysz, D. Tilki, AS. Merseburger, TM. Morgan, A. Briganti, GS. Palapattu, SF. Shariat
520    9_
$a Mutations in the BRCA1 and BRCA2 tumour suppressor genes are associated with prostate cancer risk; however, optimal screening protocols for individuals with these mutations have been a subject of debate. Several prospective studies of prostate cancer incidence and screening among BRCA1/2 mutation carriers have indicated at least a twofold to fourfold increase in prostate cancer risk among carriers of BRCA2 mutations compared with the general population. Moreover, BRCA2 mutations are associated with more aggressive, high-grade disease characteristics at diagnosis, more aggressive clinical behaviour and greater prostate cancer-specific mortality. The risk for BRCA1 mutations seems to be attenuated compared with BRCA2. Prostate-specific antigen (PSA) measurement or prostate magnetic resonance imaging (MRI) alone is an imperfect indicator of clinically significant prostate cancer; therefore, BRCA1/2 mutation carriers might benefit from refined risk stratification strategies. However, the long-term impact of prostate cancer screening is unknown, and the optimal management of BRCA1/2 carriers with prostate cancer has not been defined. Whether timely localized therapy can improve overall survival in the screened population is uncertain. Long-term results of prospective studies are awaited to confirm the optimal screening strategies and benefits of prostate cancer screening among BRCA1/2 mutation carriers, and whether these approaches ultimately have a positive impact on survival and quality of life in these patients.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a nádory prostaty $x diagnóza $x genetika $x terapie $7 D011471
650    _2
$a prostatický specifický antigen $x genetika $7 D017430
650    _2
$a časná detekce nádoru $x metody $7 D055088
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kvalita života $7 D011788
650    _2
$a geny BRCA1 $7 D019398
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    _2
$a mutace $7 D009154
650    _2
$a zárodečné buňky $x patologie $7 D005854
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a protein BRCA1 $x genetika $7 D019313
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000277688558
700    1_
$a Gandaglia, Giorgio $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France $1 https://orcid.org/0000000260042152
700    1_
$a Leapman, Michael S $u Department of Urology, Yale School of Medicine, New Haven, CT, USA
700    1_
$a Gore, John L $u Department of Urology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA
700    1_
$a Paradysz, Andrzej $u Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Department of Urology, Koc University Hospital, Istanbul, Turkey
700    1_
$a Merseburger, Axel S $u Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany
700    1_
$a Morgan, Todd M $u Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA $1 https://orcid.org/0000000211400603
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Palapattu, Ganesh S $u Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $1 https://orcid.org/0000000266276179
773    0_
$w MED00184385 $t Nature reviews. Urology $x 1759-4820 $g Roč. 20, č. 4 (2023), s. 205-216
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36600087 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132515 $b ABA008
999    __
$a ok $b bmc $g 1963171 $s 1196846
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 20 $c 4 $d 205-216 $e 20230104 $i 1759-4820 $m Nature reviews. Urology $n Nat Rev Urol $x MED00184385
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace